Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.

by Jelena Stevanović, Marjolein Pompen, Hoa H Le, Mark H Rozenbaum, Robert G Tieleman, Maarten J Postma
Published 2014-01-01

The impact of patent expiry on drug prices: insights from the Dutch market

by Simon van der Schans, Gert T. Vondeling, Qi Cao, Simon van der Pol, Sipke Visser, Maarten J. Postma, Mark H. Rozenbaum
Published 2021-01-01

Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective?

by Anouk T Urbanus, Marjolijn van Keep, Amy A Matser, Mark H Rozenbaum, Christine J Weegink, Anneke van den Hoek, Maria Prins, Maarten J Postma
Published 2013-01-01

Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis

by Sarah Pugh, Matt Wasserman, Margaret Moffatt, Susana Marques, Juan Manuel Reyes, Victor A. Prieto, Davy Reijnders, Mark H. Rozenbaum, Juha Laine, Heidi Åhman, Raymond Farkouh
Published 2020-02-01